Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravitreal Enzyme Replacement Therapy to Prevent Retinal Disease Progression in Children With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)

NCT05152914 is registered in ClinicalTrials.gov with David L Rogers, MD as lead sponsor.

NCT NCT05152914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05152914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravitreal Enzyme Replacement Therapy to Prevent Retinal Disease Progression in Children With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)
Lead sponsor
David L Rogers, MD
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 1, 2021
Completion date
March 6, 2027
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuronal ceroid lipofuscinosis type 2